Navigation Links
YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Date:1/5/2009

d trial and is being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Research and Markets has announced the addition ... report to their offering.  http://photos.prnewswire.com/prnh/20130307/600769 ... vitro growth of plant or animal cells for several ... Cell culture is a crucial step in tissue engineering ... consumables are necessary for the in vitro production of ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
(Date:7/24/2014)... 24, 2014 WIRB-Copernicus Group ® ... ethical review services for clinical research, announced today ... division of Richmond, VA -based ... and biosecurity consulting firm in the ... biosafety division – WCG Biosafety™ – will be ...
(Date:7/24/2014)... Md. , July 24, 2014  Spherix Incorporated ... the fostering and monetization of intellectual property, today announced ... the period ending June 30, 2014 on Monday, August ... call at 10 a.m. ET on Monday, August 18, ... be led by the company,s CEO, Anthony Hayes ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2
... in the sensitivity of weighing scales. Using the same ... functional nanotube radio, researchers with Berkeley Lab and the ... nanoelectromechanical system (NEMS) that can function as a scale ... atom of gold. , Alex Zettl, a physicist who ...
... SAN DIEGO, July 28 Ardea Biosciences, Inc.,(Nasdaq: ... be presented on RDEA806, the,Company,s novel investigational non-nucleoside ... virus (HIV) at,the 48th Annual ICAAC/IDSA 46th Annual ... Dr. Graeme Moyle, Director of HIV Research, Chelsea ...
... at IMAPS 2008 , ... Washington, D.C. (PRWEB) July ... proud to announce that Governor Carcieri and Dr Zolper have agreed ... on Microelectronics (IMAPS ,08) at the Providence, RI, Convention Center, November ...
Cached Biology Technology:Golden scales 2Golden scales 3Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008 2
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... research out of York University shows a surprisingly effective ... grass fungus: moose saliva (yes moose saliva). , ... saliva inhibits a grassendophyte mutualism" shows that moose and ... hosts a fungus called epichlo festucae that produces the ... toxicity. , "Plants have evolved defense mechanisms to protect ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2New imaging agent provides better picture of the gut 2
... children and young adults for influenza is being seriously underestimated, ... historic vaccine programs have concentrated on the elderly and those ... computer modeling analysis was just published in the journal ... Health. The study suggests that children in school and young ...
... June 11, 2013 (BRONX, NY) Today, researchers ... Yeshiva University convened a one-day conference on Jewish genetics ... research. Such research could help scientists identify causes and ... common disorders afflicting the general population. The ...
... guarantee future support for international scientific collaborations funded by ... on a three year budgetary framework will extend the ... At an Intergovernmental Conference hosted by the European Commission ... governments that support the Human Frontier Science Program came ...
Cached Biology News:Flu vaccines aimed at younger populations could break annual transmission cycle 2Flu vaccines aimed at younger populations could break annual transmission cycle 3Albert Einstein College of Medicine hosts conference on Jewish genetic research 2
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: